The Form 4 filing, an SEC report of insider stock activity, was filed on November 12, 2026. It lists Eric Venker as president and Immunovant CEO. The trades took place on November 10, 2026.
Roivant Sciences (ROIV) is listed in the healthcare sector and biotechnology industry.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-10 |
| Date of Latest Transaction | 2026-11-10 |
| Buy/Sell | sell |
| Transaction Count | 2 |
| Shares Transacted | 187,943 |
| Price | $40.53 |
| Total Transaction Value | $7,617,074.36 |
| Insider | |
| Ticker Symbol | ROIV |
| Company | Roivant Sciences Ltd. |
| Insider Name | Venker Eric |
| Insider Title | President & Immunovant CEO |
| Sector - Industry | Healthcare - Biotechnology |
| Holdings | |
| Total Shares Owned After Transaction | 811,211 |
| Position Size Change | 18.81% |
| Filing | |
| Filing Date | 2026-11-12 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
These were share sales, reported with transaction code S. The filing covers two sale transactions, both on November 10, 2026.
What was the average price of the transaction?
The average sale price was $40.53 per share, rounded to the nearest cent. That figure covers the shares sold across the two transactions.
How did this transaction affect the insider's holdings?
Eric Venker sold 187,943 shares and reported 811,211 shares owned afterward. He sold 18.81% of the reported shares he held before these sales.
What's the total transaction value?
The total value was $7,617,074.36 for both sales combined. That is the total amount reported for the 187,943 shares sold.
Are there any special circumstances around this transaction?
The filing information points to a Rule 10b5-1 trading plan. These plans set trading instructions in advance. Footnote text is unavailable, so it is unclear which of the two sales the plan reference covers. The date the plan was set up and its trading schedule are unknown.
For research purposes only; not investment advice.